Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Weill Cornell scientists reveal how XBP1 gene can trigger immune responses against ovarian tumors

Ovarian cancer shuts down immune system cells that would otherwise act as a first line of defense against the deadly tumor, Weill Cornell Medical College scientists report today. But a therapy that restores the cells' disease-fighting abilities could provide a powerful new strategy to attack the cancer, which kills more than 14,000 women each year.

12 Jun 2015

Nearly 15 million U.S. women have limited access to specialized gynecologic cancer care

More than one-third of counties in the Unites States are located more than 50 miles from the nearest gynecologic oncologist, making access to specialty care for ovarian and other gynecologic cancers difficult for nearly 15 million women. While most of these "low access" counties are located in the Mountain-West and Midwest regions, the findings of a recent study from researchers at the Perelman School of Medicine at the University of Pennsylvania also reveal that 47 states have at least one county located more than 50 miles from the nearest gynecologic oncologist.

12 Jun 2015

Certain ARID1a mutations sensitize some tumors to PARP inhibitor drugs

Mutations in ARID1a, which are common in many cancer types, disrupt DNA damage repair in cancer cells, allowing the cancer to progress. This gene may also be an Achilles' heel when treating certain tumors, according to a team of researchers at The University of Texas MD Anderson Cancer Center.

12 Jun 2015

New gene mutations in ADAMTS family may contribute to outcomes in ovarian cancer

There is the Addams Family. And then there is the ADAMTS family. While one is mindless entertainment, the latter may prove to be a new genetic avenue for designing ovarian cancer treatment.

11 Jun 2015

QUT cancer and eye researchers named in Queen's Birthday honours

Professor Clements is honoured for her outstanding contribution to biomedical research, particularly prostate cancer research, and for her success in generating ongoing funding to support the establishment of critically-needed national medical research facilities.

10 Jun 2015

CASI files application with CFDA to conduct ENMD-2076 Phase 2 trial in fibrolamellar carcinoma patients

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announced today that it has filed an application with China's Food and Drug Administration to conduct a Phase 2 clinical trial in fibrolamellar carcinoma (FLC) patients in China for its proprietary drug candidate, ENMD-2076.

4 Jun 2015

NW Bio releases promising new data on DCVax-Direct Phase I trial for inoperable solid tumors

Northwest Biotherapeutics, a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, over the weekend in Chicago released promising new data on their Phase I trial of DCVax-Direct for direct injection into all types of inoperable solid tumors.

2 Jun 2015

Veritas Genetics introduces genetic screen for hereditary breast and ovarian cancer risk

Boston-based Veritas Genetics is launching its mission to disrupt the genetic testing industry and bring personalized medicine and prevention to the forefront, allowing individuals to take more control of their health.

2 Jun 2015

VBL Therapeutics reports positive results from VB-111 Phase 1/2a study in recurrent platinum-resistant Müllerian cancer

VBL Therapeutics, a late-stage clinical biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced positive interim results from an investigator-initiated, Phase 1/2a trial of multiple dose VB-111 in recurrent platinum-resistant Müllerian (ovarian) cancer.

2 Jun 2015

Adaptimmune presents clinical results of NY-ESO TCR therapeutic candidate at ASCO 2015

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of TCR engineered T-cell therapy to treat cancer, today announced a poster presentation of data on its lead clinical program, an affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen, in both solid and hematologic cancers.

2 Jun 2015

Trabectedin may be better than dacarbazine for treatment of soft tissue sarcoma

Janssen Research & Development, LLC announced data from the Phase 3 multicenter study SAR3007, which demonstrated a significant improvement in progression-free survival with trabectedin (YONDELIS®) compared to dacarbazine in patients with advanced liposarcoma (LPS) or leiomyosarcoma (LMS) previously treated with an anthracycline and at least one additional chemotherapy regimen.

2 Jun 2015

Invitae introduces new patient pay program to make genetic testing more affordable, accessible

Invitae Corporation, a genetic information company, announced today the launch of its new patient pay price for its full menu of genetic tests at $475 per indication.

2 Jun 2015

Esperance announces positive results from EP-100 Phase II trial in paclitaxel-resistant ovarian cancer

Esperance Pharmaceuticals Inc. today reported positive results from a Phase II trial of lead candidate EP-100 in ovarian cancer patients resistant to paclitaxel. EP-100 is a targeted membrane-disrupting peptide designed to seek and destroy cancer cells that overexpress luteinizing hormone-releasing hormone (LHRH) receptors on their surfaces. LHRH receptors are over-expressed in a wide range of cancers.

1 Jun 2015

ASCO 2015: UH Seidman Cancer Center researchers present data from several new studies

Researchers from University Hospitals Case Medical Center Seidman Cancer Center and Case Western Reserve University School of Medicine will present data from several new studies, including a study evaluating a potential novel combination treatment for cancer patients with advanced solid tumors and a first-of-its-kind analysis of gene mutations in small cell lung cancer (SCLC), at the 51st American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago.

1 Jun 2015

Two grants to bolster research on why ovarian cancer is resistant to chemotherapy

Determining which strains of cancer will eventually become resistant to chemotherapy could be key in figuring out more effective and targeted forms of treatment. Finding the genes responsible for chemo-resistance is what Jeremy Chien, Ph.D., member of the Cancer Biology Program at The University of Kansas Cancer Center, is looking to do with an innovative system that draws inspiration from the early days of cancer gene research.

1 Jun 2015

New clinical studies on Myriad Genetics myChoice HRD companion diagnostic test presented at ASCO 2015

Myriad Genetics, Inc. today announced new clinical studies on its myChoice HRD companion diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in Chicago, Ill.

1 Jun 2015

Cancer genetic counselor helps patients make sense of genetics and statistics

Cancer was the second leading cause of death in the United States in 2013 and the American Cancer Society expects almost 10,000 new cases in New Mexico this year.

1 Jun 2015

Penn researchers to present clinical data at 2015 ASCO Annual Meeting

Researchers from the Abramson Cancer Center of the University of Pennsylvania and Penn's Perelman School of Medicine will present results from several clinical trials and other key studies during the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 through June 2.

30 May 2015

B Floral raises awareness for Ovarian Cancer Research Fund

From Los Angeles to the Hamptons, New York's premiere floral event design company, B Floral, is giving back and helping raise awareness for Ovarian Cancer Research Fund (OCRF).

30 May 2015

Myriad Genetics announces new clinical studies on myChoice HRD companion diagnostic test at ASCO 2015

Myriad Genetics, Inc. today announced new clinical studies on its myChoice HRD companion diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in Chicago, Ill.

30 May 2015

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Weill Cornell scientists reveal how XBP1 gene can trigger immune responses against ovarian tumors

Nearly 15 million U.S. women have limited access to specialized gynecologic cancer care

Certain ARID1a mutations sensitize some tumors to PARP inhibitor drugs

New gene mutations in ADAMTS family may contribute to outcomes in ovarian cancer

QUT cancer and eye researchers named in Queen's Birthday honours

CASI files application with CFDA to conduct ENMD-2076 Phase 2 trial in fibrolamellar carcinoma patients

NW Bio releases promising new data on DCVax-Direct Phase I trial for inoperable solid tumors

Veritas Genetics introduces genetic screen for hereditary breast and ovarian cancer risk

VBL Therapeutics reports positive results from VB-111 Phase 1/2a study in recurrent platinum-resistant Müllerian cancer

Adaptimmune presents clinical results of NY-ESO TCR therapeutic candidate at ASCO 2015

Trabectedin may be better than dacarbazine for treatment of soft tissue sarcoma

Invitae introduces new patient pay program to make genetic testing more affordable, accessible

Esperance announces positive results from EP-100 Phase II trial in paclitaxel-resistant ovarian cancer

ASCO 2015: UH Seidman Cancer Center researchers present data from several new studies

Two grants to bolster research on why ovarian cancer is resistant to chemotherapy

New clinical studies on Myriad Genetics myChoice HRD companion diagnostic test presented at ASCO 2015

Cancer genetic counselor helps patients make sense of genetics and statistics

Penn researchers to present clinical data at 2015 ASCO Annual Meeting

B Floral raises awareness for Ovarian Cancer Research Fund

Myriad Genetics announces new clinical studies on myChoice HRD companion diagnostic test at ASCO 2015

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in